Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Natoni

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
British Journal of Cancer|January 21, 2010
Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cellsD Mahalingam, A Natoni, M Keane, et al.
Blood Cancer Journal|July 18, 2015
Targeting the Pim kinases in multiple myelomaN A Keane, M Reidy, A Natoni, et al.
Cell Death & Disease|March 4, 2011
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variantsC R Reis, A M van der Sloot, A Natoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 19, 2022
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of TreatmentD Swan, R Henderson, C McEllistrim, et al.
Blood Advances|June 16, 2019
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 studyM O'Dwyer, R Henderson, S D Naicker, et al.
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
British Journal of Cancer|January 21, 2010
Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cellsD Mahalingam, A Natoni, M Keane, et al.
Blood Cancer Journal|July 18, 2015
Targeting the Pim kinases in multiple myelomaN A Keane, M Reidy, A Natoni, et al.
Cell Death & Disease|March 4, 2011
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variantsC R Reis, A M van der Sloot, A Natoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 19, 2022
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of TreatmentD Swan, R Henderson, C McEllistrim, et al.
Blood Advances|June 16, 2019
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 studyM O'Dwyer, R Henderson, S D Naicker, et al.
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Pageof 1